SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 222 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $766,446 | -10.8% | 27,800 | -2.8% | 0.02% | -5.3% |
Q2 2023 | $859,716 | -5.8% | 28,600 | +13.5% | 0.02% | -17.4% |
Q1 2023 | $912,996 | +99463.4% | 25,200 | -1.9% | 0.02% | -8.0% |
Q4 2022 | $917 | -99.9% | 25,700 | +0.4% | 0.02% | 0.0% |
Q3 2022 | $867,000 | +12.2% | 25,600 | -0.8% | 0.02% | +19.0% |
Q2 2022 | $773,000 | +0.7% | 25,800 | -0.4% | 0.02% | +16.7% |
Q1 2022 | $768,000 | +2.5% | 25,900 | +0.8% | 0.02% | +12.5% |
Q4 2021 | $749,000 | +9.7% | 25,700 | +0.4% | 0.02% | 0.0% |
Q3 2021 | $683,000 | -7.2% | 25,600 | +7.1% | 0.02% | -11.1% |
Q2 2021 | $736,000 | +17.2% | 23,900 | -0.4% | 0.02% | +12.5% |
Q1 2021 | $628,000 | +2.8% | 24,000 | -1.2% | 0.02% | -11.1% |
Q4 2020 | $611,000 | +20.3% | 24,300 | -0.4% | 0.02% | -21.7% |
Q3 2020 | $508,000 | +49.4% | 24,400 | +70.5% | 0.02% | +15.0% |
Q2 2020 | $340,000 | +30.3% | 14,310 | -1.4% | 0.02% | +5.3% |
Q1 2020 | $261,000 | -38.9% | 14,510 | -19.3% | 0.02% | -9.5% |
Q4 2019 | $427,000 | -19.9% | 17,990 | -7.3% | 0.02% | -25.0% |
Q3 2019 | $533,000 | -14.3% | 19,400 | -0.5% | 0.03% | -9.7% |
Q2 2019 | $622,000 | -9.5% | 19,500 | -0.5% | 0.03% | -8.8% |
Q1 2019 | $687,000 | +5.5% | 19,600 | -0.0% | 0.03% | -8.1% |
Q4 2018 | $651,000 | -43.8% | 19,603 | -14.8% | 0.04% | -26.0% |
Q3 2018 | $1,158,000 | -16.6% | 23,000 | -0.9% | 0.05% | -20.6% |
Q2 2018 | $1,389,000 | +32.4% | 23,200 | +1.3% | 0.06% | +31.2% |
Q1 2018 | $1,049,000 | +19.1% | 22,900 | +3.6% | 0.05% | +20.0% |
Q4 2017 | $881,000 | +7.4% | 22,100 | +7.8% | 0.04% | +2.6% |
Q3 2017 | $820,000 | -7.2% | 20,500 | 0.0% | 0.04% | -9.3% |
Q2 2017 | $884,000 | +38.3% | 20,500 | +0.5% | 0.04% | +34.4% |
Q1 2017 | $639,000 | +27.3% | 20,400 | +2.5% | 0.03% | +23.1% |
Q4 2016 | $502,000 | -7.4% | 19,900 | -9.1% | 0.03% | -10.3% |
Q3 2016 | $542,000 | +73.7% | 21,900 | +43.1% | 0.03% | +81.2% |
Q2 2016 | $312,000 | +34.5% | 15,300 | +0.7% | 0.02% | +33.3% |
Q1 2016 | $232,000 | +14.3% | 15,200 | +0.7% | 0.01% | +20.0% |
Q4 2015 | $203,000 | -2.9% | 15,100 | +1.3% | 0.01% | -9.1% |
Q3 2015 | $209,000 | -3.2% | 14,900 | +17.3% | 0.01% | +10.0% |
Q2 2015 | $216,000 | – | 12,700 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
S&T BANK/PA | 223,775 | $8,107 | 1.46% |
Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |